TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21502572
Drug: Revacept 10
Normalized name: Revacept
DrugBank: PR-15 (DB06037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revacept 10 mg
Study: 21502572
Drug: Revacept 20
Normalized name: Revacept
DrugBank: PR-15 (DB06037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revacept 20 mg
Study: 21502572
Drug: Revacept 40
Normalized name: Revacept
DrugBank: PR-15 (DB06037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revacept 40 mg
Study: 16332417
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive containing 20 microg ethinyl estradiol plus 0.15 mg desogestrel
Study: 16332417
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive containing 0.100 mg levonorgestrel
Study: 16332417
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive containing 0.75 mg of gestodene
Study: 12908665
Drug: Second generation
Normalized name: Second generation cephalosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second generation 'atypical' antipsychotics
Study: 11103221
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml grape-skin extract in water (1 mg extract/ml) at each of three daily meals (31.3 mg total phenolics, including 9.0 mg catechin)
Study: 27188329
Drug: Traditional DMARD
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional DMARD therapy
Study: 22252346
Drug: 60% feed
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60% feed restriction on d 4, 5, and 6 plus 1,500 mg/kg of quercetin (FR60Q)
Study: 18033957
Drug: Ticlopidine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine 200 mg once daily
Study: 12105164
Drug: EP-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP-guided therapy with ICD
Study: 12105164
Drug: EP-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP-guided therapy without ICD
Study: 31559966
Drug: T14 (triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: T14 (triple therapy for 14 days; lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg, all given twice daily)
Study: 31559966
Drug: C10 (concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: C10 (concomitant therapy for 10 days; lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg, all given twice daily)
Study: 31559966
Drug: BQ10 (bismuth
Approvals — FDA: no, EMA: no, PMDA: no
Description: BQ10 (bismuth quadruple therapy for 10 days; bismuth tripotassium dicitrate 300 mg four times a day, lansoprazole 30 mg twice daily, tetracycline 500 mg four times a day, and metronidazole 500 mg three times a day)
Study: 15014297
Drug: Ibuprofen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (10 mg/kg every 6 h until 36 h after defervescence)
Study: 15014297
Drug: Paracetamol (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (12 mg/kg every 6 h until 36 h after defervescence)
Study: 11716884
Drug: Adjuvant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemoradiotherapy (20 Gy in ten daily fractions over 2 weeks with 500 mg/m(2) fluorouracil intravenously on days 1‐3, repeated after 2 weeks)
Study: 11716884
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (intravenous fluorouracil 425 mg/m(2) and folinic acid 20 mg/m(2) daily for 5 days, monthly for 6 months)
Study: 8175136
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (14 mg/kg/body wt/day)
Study: 3330593
Drug: Enoxacin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin (single 400 mg dose)
Study: 3330593
Drug: Trimethoprim (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim (single 600 mg dose)
Study: 22994054
Drug: Compound Xuanju
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Xuanju Capsule plus tamoxifen citrate
Study: 20194828
Drug: Sertraline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline treatment for 12 weeks, titrated by clinical response
Study: 15787865
Drug: Oral cetirizine
Normalized name: cetirizine Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cetirizine 0.25 mg/kg twice daily for 18 months
Study: 2258894
Drug: co-dergocrine mesilate/nifedipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: co-dergocrine mesilate/nifedipine (4 mg/40 mg once daily)
Study: 2258894
Drug: mefruside/nifedipine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: mefruside/nifedipine (25 mg/40 mg once daily)
Study: 7422046
Drug: No specific
Normalized name: Oregano specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: No specific preparation
Study: 31303184
Drug: Micronutrient powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient powder (MNP) with 6 mg Fe plus fourteen micronutrients
Study: 21625270
Drug: Citalopram 20
Normalized name: citalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20 mg once daily for 6 months
Study: 19076190
Drug: Ultraviolet B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultraviolet B light therapy (UVB)
Study: 19076190
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PDL and UVB
Study: 14963464
Drug: apomorphine 2
Normalized name: apomorphine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: apomorphine 2 mg
Study: 2590271
Drug: Magnesium-aluminum-antacid (Mucal-Gel)
Normalized name: Magnesium Aluminum Silicate
DrugBank: Magnesium Aluminum Silicate (DB11230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium-aluminum-antacid (Mucal-Gel)
Study: 31343761
Drug: 5 protocolized
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 protocolized telephone calls added to usual treatment
Study: 30848033
Drug: LY+TT223 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY+TT223 (3 mg)
Study: 30848033
Drug: LY+TT223 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY+TT223 (2 mg)
Study: 25634940
Drug: Exercise specialist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise specialist led lifestyle program targeting increased daily walking with individualized daily pedometer step goals for the first 3 months and brisk walking speed, along with substitution of low‐relative to high‐glycemic index foods over the next 3 months.
Study: 24034079
Drug: 14-day infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-day infusion of NBP followed by NBP capsule
Study: 24034079
Drug: 14-day infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-day infusion of NBP followed by aspirin
Study: 24034079
Drug: 14-day infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-day infusion of ozagrel followed by aspirin
Study: 21516550
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for MA dependence
Study: 19079997
Drug: Prophylactic portal
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic portal vein chemotherapy (PVC) after operation
Study: 16623676
Drug: Increased protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased protein nitrogen appearance (0.2 g/kg/day)
Study: 16623676
Drug: Increased calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased calcium carbonate use (2 g/day)
Study: 12767316
Drug: Flickering light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flickering light stimulation at 100 mg/dl blood glucose
Study: 12767316
Drug: Flickering light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flickering light stimulation at 300 mg/dl blood glucose
Study: 1442596
Drug: High dosages
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosages of diuretics
Study: 1442596
Drug: Lower dosages
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dosages of diuretics
Study: 1442596
Drug: Potassium-sparing antihypertensive
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium-sparing antihypertensive regimens
Study: 3914582
Drug: Mg lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg lactate for 16 weeks
Study: 3914582
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for the first 8 weeks, followed by Mg lactate for the next 8 weeks
Study: 27206947
Drug: Combination Ezetimibe/Simvastatin/Niacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Ezetimibe/Simvastatin/Niacin (E/S/N)
Study: 27206947
Drug: Lp(a)-lowering therapies
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lp(a)-lowering therapies (systematic review)
Study: 18929475
Drug: Camphor-Crataegus berry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camphor-Crataegus berry extract combination (Korodin(®))
Study: 11849200
Drug: First antihypertensive
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First antihypertensive treatment
Study: 11849200
Drug: Second antihypertensive
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second antihypertensive treatment
Study: 11849200
Drug: Third antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third antihypertensive treatment
Study: 11849200
Drug: Gender influence
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gender influence on treatment willingness
Study: 11081784
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (8 mg once daily, increased to 16 mg after 4 weeks)
Study: 11081784
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg once daily, increased to 100 mg after 4 weeks)
Study: 3936081
Drug: Citalopram 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 25 mg
Study: 3936081
Drug: Citalopram 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 50 mg
Study: 22750851
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Personal Standards perfectionism and Evaluative Concerns perfectionism
Study: 22750851
Drug: Perfectionist conditions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfectionist conditions (High Personal Standards and Combination of Personal Standards and Evaluative Concerns)
Study: 18685047
Drug: Pain Checker
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain Checker socks (active treatment)
Study: 12844388
Drug: Low-Copper diet
Normalized name: Low-energy diets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Copper diet (0.7 mg Cu/d)
Study: 12844388
Drug: Medium-Copper diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-Copper diet (1.6 mg Cu/d)
Study: 12844388
Drug: High-Copper diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Copper diet (6.0 mg Cu/d)
Study: 8916559
Drug: BMS180048 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS180048 25 mg
Study: 8916559
Drug: BMS180048 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS180048 50 mg
Study: 8916559
Drug: BMS180048 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS180048 75 mg
Study: 8916559
Drug: BMS180048 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS180048 (25 mg, 50 mg, 75 mg)
Study: 25514686
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (group lyric analysis intervention)
Study: 25514686
Drug: Verbal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbal therapy (group talk therapy session)
Study: 25514686
Drug: Wait-list control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait-list control (eventually received group recreational music therapy intervention)
Study: 22183938
Drug: gMS‐Classifier1 (panel
Approvals — FDA: no, EMA: no, PMDA: no
Description: gMS‐Classifier1 (panel of four α‐glucose IgM antibodies)
Study: 20637969
Drug: S/N +
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: S/N + S4 (sumatriptan 4 mg SC after S/N 85/500 mg)
Study: 20637969
Drug: S/N +
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: S/N + S6 (sumatriptan 6 mg SC after S/N 85/500 mg)
Study: 20637969
Drug: S100 +
Normalized name: ADU-S100
DrugBank: ADU-S100 (DB14722)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S100 + S100 (sumatriptan 100 mg PO, 2 tablets administered 2 hours apart)
Study: 9469360
Drug: Serum HCG
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum HCG > 1,000 mIU/mL
Study: 9469360
Drug: Serum HCG
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum HCG ≤ 1,000 mIU/mL
Study: 2229465
Drug: flurazepam 30
Normalized name: flurazepam 30 mg oral capsule
DrugBank: Flurazepam (DB00690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: flurazepam 30 mg
Study: 2229465
Drug: flurazepam 15
Normalized name: flurazepam 15 mg oral capsule
DrugBank: Flurazepam (DB00690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: flurazepam 15 mg
Study: 713432
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of lysine salt of acetylsalicylic acid
Study: 713432
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of lysine salt of acetylsalicylic acid
Study: 31586871
Drug: Specific exercise
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific exercise programme (balance and jump exercises), performed at least twice per week
Study: 26142932
Drug: D3 500,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: D3 500,000 IU administered orally as 50,000 IU daily for 10 consecutive days
Study: 26142932
Drug: D2 600,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: D2 600,000 IU single mega dose administered orally
Study: 10671902
Drug: Sparfloxacin 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin 300 mg alone (Control)
Study: 10671902
Drug: Sucralfate 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 1.5 g every 12 h for five doses, with the fifth dose concurrently with sparfloxacin 300 mg (Treatment B)
Study: 10671902
Drug: Sucralfate 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 1.5 g every 12 h for five doses, with the fifth dose 2 h after sparfloxacin 300 mg (Treatment C)
Study: 10671902
Drug: Sucralfate 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 1.5 g every 12 h for five doses, with the fifth dose 4 h after sparfloxacin 300 mg (Treatment D)
Study: 9348567
Drug: Oral UFT
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral UFT plus leucovorin
Study: 8385216
Drug: alpha‐receptor blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐receptor blockade
Study: 29211308
Drug: Guadecitabine 60
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guadecitabine 60 mg/m2 on 5 consecutive days (5-day regimen)
Study: 29211308
Drug: Guadecitabine 90
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guadecitabine 90 mg/m2 on 5 consecutive days (5-day regimen)
Study: 29211308
Drug: Guadecitabine 60
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guadecitabine 60 mg/m2 on 10 consecutive days (10-day regimen)
Study: 25137863
Drug: Intravenous patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient controlled analgesia (PCA) with fentanyl
Study: 25137863
Drug: Patient controlled
Normalized name: PATIENT CONTROLLED ANALGESIA VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient controlled epidural analgesia (PCEA) with Bupivacaine 0.125% plus 2 microgram per ml fentanyl
Study: 20733448
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C and E supplementation (1000 mg vitamin C and 400 IU vitamin E daily)
Study: 18026149
Drug: High-dose melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose melphalan (200 mg/m2) after cyclophosphamide (4 g/m2) for PBPC mobilization
Study: 18026149
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy (paclitaxel and carboplatin)
Study: 10673876
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 15 mg kg‐1 (n = 21)
Study: 2181119
Drug: ticarcillin/clavulanate, 3.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ticarcillin/clavulanate, 3.1 g every six hours until clinical signs resolved
Study: 2181119
Drug: cefoxitin, 2
Normalized name: CefOXitin, 2 g injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: cefoxitin, 2 g every six hours until clinical signs resolved
Study: 7008891
Drug: Propranolol (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (1000 mg/day)
Study: 31749128
Drug: AB-kefir (Bifidobacterium
Approvals — FDA: no, EMA: no, PMDA: no
Description: AB-kefir (Bifidobacterium longum, Lactobacillus acidophilus, L. fermentum, L. helveticus, L. paracasei, L. rhamnosus, and Streptococcus thermophiles; total 10 log CFU/sachet) daily for 3 weeks
Study: 28325472
Drug: High-dose-rate (HDR)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose-rate (HDR) interstitial brachytherapy with one fraction of 19 Gy
Study: 28325472
Drug: Low-dose-rate (LDR)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose-rate (LDR) interstitial brachytherapy with 145 Gy
Study: 23194084
Drug: Dapagliflozin 1
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 1 mg/day
Study: 23194084
Drug: Dapagliflozin (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (1, 2.5, 5, or 10 mg/day)
Study: 16542747
Drug: Cisplatin 75
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m² on day 1 and gemcitabine 1,200 mg/m² on days 1 and 8, every 3 weeks for four courses (CG regimen)
Study: 16542747
Drug: Mitoxantrone 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone 10 mg/m² on day 1, methotrexate 35 mg/m² on day 1, and mitomycin 7 mg/m² on day 1, every 3 weeks with mitomycin in alternate cycles for four courses (MMM regimen)
Study: 14515196
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg prinomastat plus gemcitabine/cisplatin (GC)
Study: 14515196
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg prinomastat plus paclitaxel/carboplatin (PC)
Study: 14515196
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg prinomastat alone (post‐discontinuation of chemotherapy)
Study: 14515196
Drug: 5 or
Normalized name: Acys-5 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 or 10 mg prinomastat plus chemotherapy
Study: 11198727
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin ethyl succinate
Study: 2935242
Drug: IA FUDR
Normalized name: magnesium aluminum silicate type Ia
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA FUDR (0.3‐0.1 mg/kg/day X 14, every 28 days)
Study: 2935242
Drug: IV FUDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV FUDR (0.05‐0.15 mg/kg/day X 14, every 28 days)
Study: 27733522
Drug: Potassium nitrate
Normalized name: Potassium Nitrate
DrugBank: Potassium (DB14500)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium nitrate (7 mg/kg body weight)
Study: 1578948
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose ARA‐C (HDARAC) plus Asparaginase
Study: 1578948
Drug: Idarubicin or
Normalized name: idarubicin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin or Daunorubicin in combination with Cytarabine in a standard 3+7 protocol
Study: 1578948
Drug: Intermediate dose
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate dose ARA‐A (IDARAC) plus Mitoxantrone
Study: 1578948
Drug: Palliative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative treatment with Thioguanine and ARA‐C
Study: 22782949
Drug: 15 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 µg adjuvanted vaccine
Study: 22782949
Drug: 7.5 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 µg adjuvanted vaccine
Study: 22782949
Drug: 3.75 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 µg adjuvanted vaccine
Study: 22782949
Drug: 15 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 µg unadjuvanted vaccine
Study: 8746180
Drug: Topical fluoridation
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluoridation with 2% NaF solution before orthodontic band cementation with zinc phosphate cement
Study: 798330
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose intravenous methylprednisolone therapy at the time of kidney transplantation
Study: 31567176
Drug: Potassium-sparing diuretics
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium-sparing diuretics (e.g., spironolactone)
Study: 25386713
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (0.1 g·kg·d) during resistance training
Study: 21530799
Drug: NO dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO dietary supplement Neo40 Daily®